Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals (NASDAQ:CRBP) Rating Lowered to Hold at BidaskClub
01:28am, Tuesday, 07'th Jul 2020
Corbus Pharmaceuticals (NASDAQ:CRBP) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Tuesday, BidAskClub reports. Other equities researc
Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock?
01:58am, Monday, 06'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
AbbVie Inc (NYSE: ABBV)
ADC...
Corbus Pharmaceuticals’ (CRBP) “Buy” Rating Reaffirmed at Oppenheimer
02:50am, Wednesday, 01'st Jul 2020
Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “buy” rating reaffirmed by research analysts at Oppenheimer in a report released on Monday, AnalystRatings.com reports. They presently have a
Recent Investment Analysts’ Ratings Updates for Corbus Pharmaceuticals (CRBP)
12:22pm, Monday, 29'th Jun 2020
Corbus Pharmaceuticals (NASDAQ: CRBP) recently received a number of ratings updates from brokerages and research firms: 6/26/2020 – Corbus Pharmaceuticals was upgraded by analysts at BidaskClub from
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum.
Karuna Program Progress, And Other News: The Good, Bad And Ugly Of Biopharma
01:42am, Friday, 26'th Jun 2020
Karuna's clinical program for acute psychosis is about to proceed. Corbus reports progress for its phase 2 program. Myovant reports positive data for relugolix.
VBI Vaccines (VBIV) Receives a Buy from Oppenheimer - Markets
11:01am, Tuesday, 23'rd Jun 2020
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on VBI Vaccines (VBIV – Research Report),
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
12:05pm, Monday, 22'nd Jun 2020
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background.
NI woman opens up about CF battle and helping others after surviving ICU
07:28pm, Sunday, 21'st Jun 2020
The Newtownabbey woman is giving something back with new clothing brand '65 roses'
2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains
02:56pm, Thursday, 18'th Jun 2020
As the number of new COVID-19 infections spikes, so has market volatility. An uptick in cases in the U.S. and China has spurred the latest burst of swings, with both the S&P; 500 and Dow Jones followi
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?
12:51pm, Thursday, 18'th Jun 2020
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Given Consensus Rating of “Buy” by Analysts
03:12am, Monday, 15'th Jun 2020
Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) have been given a consensus rating of “Buy” by the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One
Oppenheimer Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR) - Markets
03:11am, Monday, 15'th Jun 2020
Oppenheimer analyst Leland Gershell maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) yesterday and set a price
Zacks Investment Research Downgrades Corbus Pharmaceuticals (NASDAQ:CRBP) to Hold
03:54am, Wednesday, 10'th Jun 2020
Corbus Pharmaceuticals (NASDAQ:CRBP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports. Acc
